MAM
TVTX icon

Martingale Asset Management’s Travere Therapeutics TVTX Stock Holding History

Martingale Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,304
Closed -$158K – 844
2024
Q3 		$158K Hold
11,304
– – ﹤0.01% 775
2024
Q2 		$92.9K Buy
+11,304
New +$76.1K ﹤0.01% 779
2023
Q4 		– Sell
-20,203
Closed -$181K – 850
2023
Q3 		$181K Sell
20,203
-24,800
-55% -$350K ﹤0.01% 755
2023
Q2 		$691K Sell
45,003
-4,700
-9% -$85.5K 0.01% 536
2023
Q1 		$1.12M Buy
49,703
+200
+0.4% +$4.25K 0.02% 418
2022
Q4 		$1.04M Buy
49,503
+10,988
+29% +$233K 0.02% 439
2022
Q3 		$950K Buy
38,515
+23,315
+153% +$602K 0.02% 456
2022
Q2 		$369K Buy
+15,200
New +$382K 0.01% 706
2021
Q2 		– Sell
-18,615
Closed -$465K – 899
2021
Q1 		$465K Sell
18,615
-1,400
-7% -$38.7K 0.01% 628
2020
Q4 		$547K Sell
20,015
-75,800
-79% -$1.77M 0.01% 592
2020
Q3 		$1.77M Sell
95,815
-95,500
-50% -$1.86M 0.02% 454
2020
Q2 		$3.91M Buy
+191,315
New +$3.05M 0.05% 364

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Martingale Asset Management's TVTX Position: Q4 2024 in Review

Martingale Asset Management sold out of Travere Therapeutics (TVTX) in Q4 2024, closing a stake of 11,304 shares — an estimated $158K sold.

Martingale Asset Management first reported a position in TVTX in Q2 2020 and held it in 12 quarters. The position peaked at $3.91M in Q2 2020. 197 funds tracked by Wall St. Rank hold TVTX as of Q4 2024.

  • Martingale Asset Management reported no remaining Travere Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Martingale Asset Management sold 11,304 Travere Therapeutics shares in Q4 2024, an estimated $158K.
  • Martingale Asset Management first reported a position in Travere Therapeutics in Q2 2020 and held it in 12 quarters.
  • Martingale Asset Management's Travere Therapeutics position peaked at $3.91M in Q2 2020.
  • 197 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2024.

Based on Martingale Asset Management's 13F filing for Q4 2024, filed 13 Feb 2025.